Biogen (BIIB) - 26 Year Stock Price History

Historical daily stock prices for Biogen since 1991 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Biogen (BIIB) as of November 17, 2017 is 313.97.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $66.397B $11.449B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.